[October 20, 2014]

Research and Markets: Roche/Genentech's Herceptin (trastuzumab) HER2-Positive Breast Cancer Treatment Report 2014 - Forecast and Market Analysis to 2023

Research and Markets (http://www.researchandmarkets.com/research/wst32n/herceptin) has announced the addition of the "Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023" report to their offering.

Roche/Genentech's Herceptin (trastuzumab), first approved in the US in 1998, and in the EU in 2000, is the gold-standard treatment for HER2-positive breast cancer, and is prescribed both for patients with early-stage and metastatic disease. Herceptin is an intravenously-administered mAb that targets the HER2 receptor, blocking the downstream signaling pathways that support tumor cell survival (Genentech, 2013).

• Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Herceptin including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Herceptin for the top eight countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

• Etiology and Pathophysiology
• Basic Breast Anatomy
• Breast Cancer Staging
• Prognosis (News - Alert)
• Quality of Life
• Symptoms

4 Disease Management

• Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB)
• Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA)
• Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV)

5 Competitive Assessment

6 Herceptin (trastuzumab)

• Efficacy
• Safety
• SWOT Analysis
• Forecast

7 Appendix

For more information visit http://www.researchandmarkets.com/research/wst32n/herceptin

[ Back To TMCnet.com's Homepage ]